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Summary 
Antinudear antibodies (ANAs) reactive with a limited spectrum of nuclear antigens are characteristic 
of systemic lupus erythematosus (SLE) and other collagen vascular diseases, and are also associated 
with certain viral infections.  The factors that initiate ANA production and determine ANA 
specificity are not well understood. In this study, high titer ANAs specific for the p53 tumor 
suppressor protein were induced in mice immunized with purified complexes of murine p53 
and the Simian virus 40 large T antigen (SVT), but not in mice immunized with either protein 
separately. The autoantibodies  to p53 in these mice were primarily of the IgG1 isotype, were 
not cross-reactive with SVT, and were produced at titers up to 1:25,000, without the appearance 
of other autoantibodies. The high levels  of autoantibodies to p53 in mice immunized with p53/SVT 
complexes were transient, but low levels of the autoantibodies  persisted. The latter may have 
been maintained by self antigen, since the anti-p53,  but not the SVT, response in these mice 
could be boosted by immunizing with murine p53. Thus, once autoimmunity to p53 was established 
by immunizing with p53/SVT complexes, it could be maintained without a requirement for 
SVT. These data may be explained in at least two ways. First, altered antigen processing resulting 
from the formation of p53/SVT complexes might activate autoreactive T  helper cells specific 
for cryptic epitopes of routine p53,  driving anti-p53  autoantibody production. Alternatively, 
SVT-responsive T  cells may provide intermolecular-intrastructural help to B cells specific for 
murine p53. In a second stage, these activated B cells might themselves process self p53, generating 
p53-responsive autoreactive T  cells. The induction of autoantibodies  during the course of an 
immune response directed against this naturally occurring complex of self and nonself antigens 
may be relevant to the generation of specific autoantibodies  in viral infections,  and may also 
have implications for understanding the pathogenesis of ANAs in SLE. In particular, our results 
imply that autoimmunity can be initiated by a "hit and run" mechanism in which the binding 
of a viral antigen to a self protein triggers an immune response that subsequently can be perpetuated 
by self antigen. 
1  /'~ertain antinudear antibodies (ANAs)  are specific mark- 
~.~ ers for autoimmune disease subsets such as SLE, sdero- 
derma, or polymyositis  (1). Many of the antigenic targets 
of ANAs are multiprotein complexes or complexes of pro- 
teins with nucleic adds, and it has been suggested that the 
particulate nature of these antigens might be important for 
their antigenicity (2). In some respects, the immune responses 
to particulate autoantigens in SLE may be analogous to im- 
1 Abbreviations used in this paper: AcMNPV, Autographa californica  nuclear 
polyhedrosis virus; ANA, antinuclear anuqx~dy; MMB, mixed micelle buff; 
Sf-9, Spodoptera  frugiperda ovary cell line; SVT, SV40 large T  antigen. 
mune responses to viral particles. Viral particles are taken up 
and processed by APCs as a unit, and T cells specific for a 
single polypeptide component of a viral particle may provide 
help to B cell dories specific for several components of the 
same particle  (3-9).  This  has been referred  to  as "inter- 
molecular-intrastructural help" (10). In the special case of 
a complex consisting  of both foreign and self antigens,  T 
cells specific  for nonself components might drive the produc- 
tion of autoantibodies  to the self components (11). 
Another way in which a complex of self and nonsdf an- 
tigens might induce autoimmunity is by altering the pro- 
cessing of a self antigen, with activation ofT ceils responsive 
to minor "cryptic" epitopes to which tolerance is incomplete 
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can be influenced greatly by protein-protein interactions, such 
as dimerization (15, 16), it is conceivable  that a nonself an- 
tigen could alter the processing of a bound autoantigen by 
APCs, thereby stimulating T cells specific for cryptic sdfepi- 
topes. In the present studies, we have examined the hypoth- 
esis that comple~,es of self and nonself  antigens might trigger 
autoimmunity. We report  that autoimmunity to  the p53 
tumor suppressor  protein can be induced in BALB/c mice 
immunized with complexes of  p53 and the SV40 large T an- 
tigen (SVT).  Although p53/SVT complexes  were essential 
for inducing autoimmunity, p53 alone was sufficient to main- 
rain it, suggesting that the binding of SVT to p53 alters an- 
tigen processing and activates  T  cells responsive  to cryptic 
epitopes of p53  which drive autoantibody production. 
Materiah and Methods 
Cell Lines and Viruses.  The Sf-9 ($podoptera frugiperda ovary) 
cell line was obtained from the American Type  Culture Collection 
(ATCC, Rockville, MD), and maintained in Grace's insect tissue 
culture medium supplemented  with 3.3 g/l TC yeastolate,  3.3 g/liter 
lactalbumin hydrolyzate (from the UNC Linebergor Comprehen- 
five Cancer Center T~ssue  Cuhure Facih'ty),  10% fetal  bovine  serum, 
and penicillin/streptomycin (TNM-FH medium). Wild-type Au- 
tographa californica nuclear polyhedrosis virus (AcMNFV) was ob- 
tained from Dr. Elmer M. Price (University of North Carolina at 
Chapel Hill). The recombinant  baculoviruses  vEV55SVT (directing 
the expression of full-length SVT) and vEV55p53 (directing the 
expression of full-length wild-type murine p53) were provided by 
Dr. L. K. MiLler (University of Georgia, Athens, CA) (17). 
Monodonal Antibodie~  Hybridoma cells  producing  mAbs specific 
for SVT (PAb 101, IgG2a of BALB/c origin) (18) and p53 (PAb 
122, IgG2b of  BALB/c  origin) (19) were obtained from the ATCC. 
The mAbs were partially purified from culture supernatant by am- 
monium sulfate precipitation. For some experiments, mAbs were 
purified  from hybridoma  culture supernatants  onto protein A--Sepha- 
rose beads (Pharmacia, Piscataway,  NJ). Isotype control mAbs 162 
(IgG2a anti-Ku) and N3H10 (IgG2b anti-Ku) have  been described 
previously (20). 
Cell Labeling.  Sf-9  cells were infected with baculoviruses at a 
multiplicity of  infection of 20 as described (21), incubated for 24 h 
at 27~  and metabolically  labded for an additional 18 h at 27~ 
in methionine-deficient  TNM-FH medium containing 5% dialyzed 
fetal  bovine serum, 3% regular TNM-FH medium (containing me- 
thionine) and 25/zCi/ml [3SS]methionine  and [3SS]cystdne  (Tram- 
label; ICN, Costa Mesa, CA). The cells were detached by pipet- 
ting gently, collected by centrifugation, washed once with PBS, 
and sonicated  at 5 x  10  s ceLls/ml  in ice-cold lysis  buffer containing 
0.15 M NaC1, 50 mM "Iris, pH 7.5, 2 mM EDTA, 0.3% NP-40, 
0.5 raM PMSF, and aprotinin (0.3 trypsin inhibitor units/m1). The 
cell lysate was cleared by centrifuging twice for 10 rain each at 
11,000 g before immunoprecipitation. 
Immunoprecipitation.  PAb 101 or PAb 122 culture supernatant 
100-300/~1 was added to 200/L1 (10  s cell equivalents) of radiola- 
beled Sf-9 cell extract for 1.5 h at 4~  For mouse sera, 10 #1 of 
rabbit anti-mouse IgG antibodies (1 mg/ml, provided  by Dr. Robert 
Eisenberg, University of North Carolina, Chapel Hill, NC) plus 
1-5/~1 of mouse serum was added to the same volume of cell ex- 
tract. After centrifuging 15 rain at 11,000 g, protein A-Sepharose 
beads (30/~1 of  a 50% slurry in water) were added for an additional 
2 h at 22~  Unless otherwise indicated, the beads were washed 
twice with mixed miceile buffer ([MMB] 150 mM NaC1, 50 mM 
Tris, pH 7.5, 2 mM EDTA, 0.25 M sucrose, 0.5% SDS, 2.5% Triton 
X-100) at 4~  and then with NET buffer (0.15 M NaC1, 2 mM 
EDTA, 50 mM Tris, pH 7.5). In some cases, the immunoprecipi- 
tates were washed twice with 50 raM Tris, pH 7.5, 2 mM EDTA, 
0.3% NP-40 containing NaC1 at 0.15, 0.5, or 1.5 M NaC1, or once 
with the same buffer containing 1.5 M NaC1, then with MMB, 
and then with NET buffer. Immunoprecipitated  proteins were ana- 
lyzed on 10% SDS-polyacryhmide  gels which were fluorographed, 
dried, and exposed to x-ray film (22). 
In other experiments,  human K562 (erythroleukemia)  and murine 
SP2/0 (nonsecreting myeloma) cells were labeled with [3SS]me- 
thionine and cysteine  exactly as described (20). Extracts of the cells 
were immunopredpitated using preimmune and immune sera from 
the mice immunized with p53/SVT complexes, p53, or SVT. The 
immunoprecipitates were washed with MMB and NET buffers as 
described above, and proteins remaining associated  with the pro- 
tein A-Sepharose  beads were analyzed  by SDS-PAGE and autoradi- 
ography. 
Immunization of Mice.  BALB/c  mice (6-8-wk old female, four 
per group) were obtained  from The Jackson  Laboratory  (Bar Harbor, 
ME) or Charles River (Wilmington,  MA). Protein A-Sepharose 
beads (40/~1 of a 50% slurry in PBS) were incubated for 1.5 h 
with 100/~1 of hybridoma supernatant from PAb 101 or PAb 122, 
and then washed with PBS. The mAb-coated beads were then in- 
cubated for 1.5 h at 4~  with Sf-9 cell lysate (200/~1 =  2  x  106 
cell equivalents)  containing the recombinant  p53 (cells  infected  with 
vEV55p53), SVT (cells infected with vEV55SVT), or p53/SVT 
complexes (cells coinfected with both viruses). The beads were 
washed as before, resuspended in 100/~1 of PBS, and emulsified 
with CFA for the initial immunization or IFA for subsequent in- 
jections. Mice were injected  with beads every  2 wk. Serum samples 
were obtained at days  0 (preimmune), 14, 28, and 42. The amount 
of antigen attached to the affinity  beads was estimated by Western 
blotting using antibodies specific  for p53 or SVT as described  below, 
and by Coomassie blue staining and comparison with standard 
amounts of BSA. 
In some  experiments, mice  immunized three times  with p53/SVT 
complexes were immunized once, 18 wk after the last p53/SVT 
injection, with murine p53 affinity  purified on PAb 122 as described 
above. Serum was obtained 9 d later and tested for anti-p53 and 
anti-SVT antibodies by ELISA (see below). 
Iramunobtotting.  Sf-9  cells infected with wild-type AcMNPV, 
vEV55p53, or vEV55SVT were solubilized  directly in SDS sample 
buffer, and the lysates  were fractionated  on 10% SDS-polyacrylamide 
gels and transferred to nitrocdlulose (20). Immunoblot analysis  of 
the recombinant proteins was performed using sera collected from 
the mice at 2-wk intervals (1:500 dilution for 1.5 h), or PAb 101 
or PAb 122 culture supernatants  at a 1:5 dilution. Second  antibodies 
were alkaline  phosphatase-conjugated  goat anti-mouse IgG (3' chain 
specific) antibodies (IgG plus L chain specific; Tago, Inc., Burlin- 
game, CA) (1:1,000 dilution for 1.5 h). In some experiments, the 
second antibodies were alkaline phosphatase-conjugated  goat 
anti-mouse 3" 1, 2a, or 2b H chain-specific  antibodies (Fisher Bio- 
tech, Pittsburgh, PA). Blots were developed  with nitroblue tetrazo- 
lium/5-bromo-4-chloro-3-indolyl  phosphate (Bio-Rad, Richmond, 
CA). 
Afllnity Purification of Antibodies.  Antibodies specific for mu- 
rine p53 or SVT were affinity purified from nitrocellulose strips 
cut from Western blots using the procedure of Smith and Fisher 
(23). Briefly,  the afanity-purified antibodies were eluted from the 
nitrocellulose  strips with 50 mM glycine HC1 buffer (pH 2.5) plus 
0.5 M NaC1, 0.5% (vol/vol) Tween 20, and 100 #g/ml BSA, and 
1244  Autoimmunity  to the p53 Tumor Suppressor Protein neutralized immediately with 0.5 M NazHPO4 buffer. The affin- 
ity-purified antibodies were diluted 1:15 and used to probe fresh 
Western  blots of  cell  extracts derived  from vEV55SVT or vEV55p53 
infected Sf-9 ceils. 
ELISA for anti-p53 and anti-SVT.  ELISAs  for detecting anti- 
bodies to p53 or SVT in routine sera were a modification of the 
antigen capture assays described previously for Ku (24). Briefly, 
microtiter plates (Immunoplate MaxiSorp; Nunc, Inc., Naperville, 
IL) were coated overnight at 4~  with partially purified PAb 122 
(anti-p53 ELISA)  or PAb 101 (anti-SVT  ELISA)  at 10 ~g/ml, washed 
once, and blocked with PBS containing 10% bovine calf serum. 
Cell extract from Sf-9  cells  infected  with vEV55p53 or VEV55SVT 
was added to the wells for 1.5 h (4  x  10  s cell equivalents/wel). 
The wells were washed and then incubated with murine sera at 
a  1:250 dilution for 1.5 h. After washing again, second antibody 
(alkaline phosphatase-conjugated goat anti-mouse 3' 1 H chain- 
specific antibodies, 1:1,250 dilution) was added for 1.5 h. The wells 
were washed and developed  with  p-nitrophenylphosphate substrate 
(Sigma Chemical Co., St. Louis, MO), and OD at 405 nra was 
determined as described (22). The serum binding to control wells 
(coated with antibody but no antigen) was determined in paralld, 
and subtracted  from the optical  density  of  the corresponding  antigen- 
coated wells. 
Results 
Expression of  Antigens.  Fuil-length recombinant SVT and 
murine p53 were expressed in Sf-9 ceils using recombinant 
baculoviruses vEV55SVT and vEV55p53, respectively  (17). 
As shown in Fig. 1 A, Sf-9 eels infected with vEV55SVT 
expressed a 3sS-labeled protein of *97 ED that was immu- 
noprecipitated by PAb 101 (anti-SVT)  but not PAb 122 (anti- 
p53)  and was absent in extracts of Sf-9 ceils infected with 
vEV55p53 or wild-type AcMNFV. In contrast, Sf-9 eels in- 
fected with vEV55p53  expressed  a  3sS-hbded  protein  of 
'~53 kD that was immunoprecipitated by PAb 122 but not 
PAb 101, and was absent in extracts of ceils infected with 
vEV55SVT  or wild-type AcMNtN. 
When  Sf-9  ceils  were  coinfected for  24  h  with  both 
vEV55SVT  and vEV55p53  and labeled with [3SS]methio- 
nine, both p53 and SVT could be immunoprecipitated effi- 
ciently by either PAb  101 or PAb  122, consistent with the 
formation of a complex of the two proteins (Fig. 1 B). Both 
p53 and SVT remained associated with the beads after washing 
with 50 mM Tris, pH 7.5, 2 ram EDTA, 0.3% NP-40 con- 
raining 0.15 M (Fig.  1 B, lane 1), 0.5 M (lane 2), or 1.5 M 
(lane 3) NaC1, or 1.5 M NaC1 buffer followed  by MMB (lane 
4), or MMB (lane 5), indicating that the affinity  beads could 
be washed under a variety of conditions without dissociating 
the p53/SVT complex. In other experiments, we found that 
this complex also formed readily in vitro (data not shown). 
Consistent with previous observations (17), there was no evi- 
dence that an insect homolog of p53 could be immunopre- 
Figure  1.  Immunoprecipitation  analysis  of protein e~pression in recombinant  baculovirus  infected  insect ceils and p53/SVT complex  formation  in 
insect ceils.  Sf-9  ceils  were  infected  with vEV55SVT (SVT), vEV55p53 (p53),  wild-type  AeMNPV (wt)  (A), or coinfected  with vEV55SVT  and vEV55p53 
(/3). After 24 h, ceils were hbded with [~sS]methionine  and cysteine  and extracts were immunoprecipitated  with PAb 101 or PAb 122. (A) Single 
infection of Sf-9 ceils. Immunoprecipitates  were washed  with 50 ram Tris, pH 7.5, 2 mM EDTA, 0.3% NP-40 containing  0.15 M NaC1, eluted  by 
boiling in SDS sample buffer, and analyzed  by SDS-PAGE and autoradiography.  PAb 101 immunopreeipitated  a "~97-kD protein only  from lysates 
of cells infected  with vEV55SVT, whereas PAb 122 immunoprecipitated  a '~53-ED protein present only  in lysates  of calls infected  with vEV55p53. 
(B) Coinfected  ceils. Immunoprecipitates  of coinfected  Sf-9 ceils using PAb 101 or PAb 122 were washed with 50 mM Tds, pH 7.5, 2 mM EDTA, 
0.3% NP-40 containing: 0.15 M NaCI (hne/), 0.5 M NaC1 (lane  2), 1.5 M NaC1 (lane 3), 1.5 M NaC1 followed  by MMB (lane 4), or MMB (lane 
5). Immunoprecipitated  proteins were separated  by SDS-PAGE, and the gd was fluorographed,  dried, and exposed to XAR-5 film  for 2 d. Positions 
of  molecular  weight  standards  (in kD) are indicated.  (C) Estimation  of the quantity  of antigens. Antigens  were affinity  purified  on protein  A-Sepharose 
beads coated  with either PAb 101 (p53/$VT complex  and 8VT) or PAb 122 (p53). Proteins  were  eluted  from the beads by boiling  in 25/~1SDS sample 
buffer, and 3/~1 of each sample  was anaiyzed  by SDS-PAGE and transferred  to nitrocellulose.  Blots  were probed with PAb 122 (anti-p53) or PAb 101 
(anti-SVT), followed  by alkaline  phosphatase-conjugated  goat anti-mouse IgG (3' and L chain specific) antibodies. Note that small amounts of H 
and L chains were detectable on the blots, and that mouse 3' H chain displays an electrophoretic  mobility  similar to that of the p53 protein. 
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due to formation of a complex with SVT (Fig.  1 A). 
The formation of a p53/SVT complex with a prolonged 
intracellular half-life compared with that of free p53 has been 
shown previously, and is thought to be a crucial step in trans- 
formation by SV40 and the related JC and BK viruses (25). 
Despite  the short half-life of free p53 in mammalian cells, 
recombinant routine p53, SVT, and p53/SVT complex were 
all expressed at extremdy high levels in Sf-9, making it pos- 
sible to affinity purify large quantities  of antigen from in- 
fected cells. The recombinant antigens comigrated on gels 
with the SVT antigen in Cos-1 cells, and the cellular p53 
antigen, respectively (data not shown). 
Induction of Autoantibodies to p53.  The potential role of 
p53/SVT complexes in inducing autoantibodies  to p53 was 
investigated by immunizing mice with complexes affinity 
purified on protein A-Sepharose beads. Extracts of Sf-9 cells 
infected with vEV55SVT or vEV55p53 alone, or coinfccted 
with both viruses, were incubated with protein A-Sepharose 
beads coated with PAb 101 (vEV55SVT and vEV55SVT plus 
vEV55p53 extracts) or PAb 122 (vEV55p53 extract). Western 
blots indicated that comparable amounts of p53, SVT, and 
p53/SVT complex were injected into the different  groups 
of BALB/c mice (Fig. 1 C), and Coomassie blue staining with 
comparison to a standard protein (BSA) showed that ,v 1/~g 
of p53,  SVT, or both (in the case of p53/SVT complexes) 
could be purified on 40/~1 of packed protein A-Sepharose 
beads coated with PAb 101 or PAb 122 (data not shown). 
Mice were screened for the production of anti-SVT  and 
anti-p53  antibodies  by  immunoprecipitating  3sS-labeled 
vEV55p53 or vEV55SVT infected Sf-9 cells using preimmune 
and immune sera collected at 2, 4, and 6 wk (Fig. 2). All 
four  mice  immunized  with  SVT/p53  complexes  affinity 
purified using PAb 101 affinity beads produced antibodies that 
immunoprecipitated both p53 and SVT efficiently starting 
at 4 wk. Immunoprecipitations of p53  and SVT by serial 
sera from a representative mouse immunized with p53/SVT 
complexes are shown in the top and bottom panels, respec- 
tively, of Fig. 2. In contrast, four mice immunized with p53 
did not develop antibodies  to either p53 or SVT. All three 
mice immunized with SVT produced anti-SVT  antibodies 
beginning 2 wk after immunization and, unexpectedly, two 
of the mice displayed a weak reaction with p53 at 6 wk by 
immunoprecipitation, whereas serum from the third mouse 
Figure 2.  Immunoprecipitarion 
analysis of sera from mice immu- 
nized with p53, SVT, or p53/SVT 
complex. BALB/c mice were im- 
munized once with antigen-coated 
affinity beads in CFA,  and twice 
more at 2-wk intervals with beads 
in  IFA  as  follows:  p53  from 
vEV55p53-infected  cells purified 
on  pAb  122  beads;  SVT  from 
vEV55SVT-infected  ~  purified  on 
PAb 101 beads; and p53/SVT com- 
plex from coinfected cells purified 
on PAb 101 beads. Serum samples 
were  collected  at  0  wks  (preim- 
mune),  and  at  2,  4,  and 6  wk 
after the first immunization. Sera 
were screened for antibodies to p53 
and SVT by immunoprecipitating 
3sS-iabeled  vEVSSpS3 (top) or vEV- 
55SVT (bottom)  inked Sf-9  ceU  ly- 
sates with 5/A of serum collected 
at 0, 2, 4, and 6 wk. (p53)  Sera  from 
a mouse immunized with affinity 
purified p53;  (SVT) sera from  a 
mouse  immunized with  affinity 
purified SV'~ (p53/SVT)  sera from 
a mouse immunized with affinity- 
purified p53/SVT compl~s. Con- 
trol immunoprecipitates using pro- 
tein  A-Sepharose  beads  without 
serum are shown for each extract. 
Immunoprecipitation  of  recom- 
binant p53 and SVT by PAb122 or 
PAbI01, respectively, is shown for 
comparison.  Immunoprecipitated 
proteins  were  analyzed by SDS- 
PAGE, and autoradiographed.  Po- 
sitions of molecular  weight stan- 
dards (in kD) are indicated. 
1246  Autoimmunity to the p53 Tumor Suppressor Protein was negative. The induction of  autoantibodies to murine p53 
was not dependent on the use of PAb 101 to affinity purify 
the antigen, since autoantibodies to p53 were also produced 
by mice immunized  with p53/SVT complexes  affinity purified 
on PAb 122 beads (data not shown). 
Analysis of Autoantibodies by Western Blot 
The production of  autoantibodies to p53 in mice immunized 
with SVT/p53 complexes  was confirmed by Western blot (Fig. 
3 A). Sera from the mice immunized with p53/SVT com- 
plexes, but not those from mice immunized  with p53 or SVT 
alone, showed a strong reaction with recombinant murine 
p53 expressed  in Sf-9 cells and its proteolytic degradation frag- 
ments. The sera appeared to recognize the degradation frag- 
ments more strongly than intact p53, in contrast to PAb 122, 
which recognized the intact murine p53 protein as well as 
its degradation products (Fig. 3 A, right). Antibodies to SVT 
were, in general, less reactive on immunoblots, but the ex- 
pression of SVT in the baculovirus  system was also some- 
what less efficient than that of  p53, suggesting that this may 
have been partially related to a lower amount of SVT than 
p53 loaded on the gel. Using subclass-specific second anti- 
bodies in the Western blot assay, the autoantibodies  to p53 
as well as the antibodies to SVT were found to be primarily 
of the IgG1 isotype (data not shown). IgG2b and IgG3 anti- 
bodies to p53 and IgG2b antibodies to SVT were also de- 
tected by Western blot  in  sera of mice immunized with 
p53/SVT complexes, but at considerably lower levels. 
To exclude the possibility that the autoantibodies  to rou- 
tine p53 were a population of cross-reactive anti-SVT anti- 
bodies,  the specificities of affinity-purified antibodies  were 
examined. Antibodies were affinity purified from nitroceLlu- 
lose strips as described (23). To permit affinity purification 
of anti-SVT antibodies from nitrocellulose strips, the amount 
of cell extract from Sf-9 ceLls  infected with vEV55SVT was 
increased  relative to the amount of  cell extract from vEV55p53 
infected cells (Fig. 3 B, left). Using approximately four times 
as much SVT extract, serum from a mouse immunized with 
p53/SVT compkaes could be shown to bind on Western blots 
to SVT as well as p53  (Fig. 3 B, serum). Antibodies from 
that serum were affinity purified on recombinant murine p53 
and were highly specific  for p53 when used to probe a second 
immunoblot (p53 aflln), whereas antibodies affinity purified 
on SVT were highly specific  for SVT, and displayed no cross- 
reactivity with p53 (SVT aflln). These studies suggested that 
autoantibodies  to p53 were a different population than the 
antibodies to SVT in the sera of mice immunized with p53/ 
SVT complexes. 
Analysis of Autoantibod2/ Production ~  ELISA 
Antigen capture ELISAs for IgG1 antibodies to p53 (based 
on the IgG2b mAb PAb 122) and SVT (based on the IgG2a 
mAb PAb 101) were used to examine the titer and time course 
of autoantibody production in this model. The assays were 
similar in design to an anti-Ku ELISA in use in our labora- 
tory (24), but utilized  an IgG1 specific second antibody. 
Antibody titers.  As shown in Fig. 4 A, a representative 
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Figure  3.  Western blot analysis of antibody production in mice im- 
munized with p53, SVT, and p53/SVT.  (A) Western blots using whole 
sera. Pellets of Sf-9 cells infected with vEV55p53  (p53, left lane of each 
panel)  or vEV55SVT  (SVT,  fight lane of each panel)  were sohbilized 
in SDS-sample buffer, and subjected to SDS-PAGE and Western blot anal- 
),sis using 1:500 diluted mouse sera collected 6 wk after the first immuni- 
zation followed by alkaline phosphatase-conjugated goat anti-mouse IgG 
antibodies. Sera from mice immunized with p53, SVT, or p53/SVT com- 
plea~s (two mice) were analyzed. Immunoblots with PAb 101 (anti-SVT) 
and PAb 122 (anti-p53)  were performed for comparison, Autoantibodies 
reactive by Western blotting with p53 were more readily detectable than 
those to SVT. This is in part due to the smaller amount of recombinant 
SVT than p53 loaded on the gel. However, in other experiments, the level 
of anti-SVT antibodies reactive on Western blot appeared to be lower than 
the level of anti-p53 antibodies (data not shown). (B) Specificity of affinity- 
purified antibodies. Immunoblots were performed using serum ofa BALB/c 
mouse immunized with p53/SVT comple~:es  (serum) that contained anti- 
bodies to SVT as well as autoantibodies to p53. Autoantibodies to p53 
were duted from the blot as described  in Materials and Methods. The 
affinity-puritled antibodies were neutralized and used to probe a similar 
Western blot (p53 aflin). Likewise, antibodies to SVT were aff~ty purified 
from the serum, and used to probe another blot (SVT aflin). Antibodies 
affinity purified from the p53 band were specific for p53, whereas  those 
purified from SVT were specific for SVT. Immunoblots with mAbs PAb 
122 (anti-p53) and PAb 101 (anti-SVT) are shown for comparison. mouse serum collected 1 wk after the third immunization 
with p53/SVT complexes displayed strong reactivity with 
SVT in the anti-SVT antigen capture ELISA at a titer of 
,~1:25,000.  Weaker reactivity (titer "~1:250) with PAb 101 
alone, which was used to affinity purify the p53/SVT com- 
plexes for immunizing the mice, was also apparent. Binding 
to an irrelevant IgG2a (anti-Ku mAb 162) was comparable, 
suggesting that the weak binding to PAb 101 is attributable 
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Figure 4.  Antibody  titers  by ELISA. (.4) Titer oflgG1 anti-SVT  anti- 
bodies. Serum  from a mouse  immunized  three times  with p53/SVT com- 
plexes was tested  for antibodies to SVT by antigen capture ELISA  based 
on PAb 101 (lgG2a). Second  antibody  was 1:1,250 ~lk~line  phosphatase-con- 
jugated goat anti-mouse  IgG1. (0) Binding to wells coated  with PAb 
101 plus recombinant  SVT (values  were  corrected  for binding to PAb 101 
alone); (V) binding to PAb 101 alone; (V) binding to anti-Ku mAb 162 
(IgG2a isotype  control). (B) Titer of anti-p53 antibodies. Serum  from the 
same mouse  shown  in A was tested  for antibodies to p53 by antigen  cap- 
ture ELISA  based on PAb 122 (IgG2b). Second  antibody  was 1:1,250 alka- 
line phosphatase-conjugated  goat anti-mouse  IgG1. (0) Binding  to wells 
coated with PAb 122 plus recombinant  p53 (values were corrected  for 
binding to PAb 122 alone); (V) binding to PAb 122 alone; (V) binding 
to anti-Ku mAb N3H10 (IgG2b isotype control). 
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to rheumatoid factor (anti-Fc) activity. This argues against 
the possibility that the autoantibodies to p53  are internal 
image-type antibodies antiidiotypic to PAb 101. Moreover, 
p53/SVT  complexes affinity purified with either PAb 122 
or PAb 101 induced autoantibodies to p53, and PAb 101 was 
found to immunoprecipitate p53/SVT complexes efficiently 
(Fig. 1/3), further supporting the interpretation that the anti- 
p53 autoantibodies were not antiidiotypic (internal image) 
antibodies induced by PAb  101. 
Examination of the binding of serum to p53 in the anti- 
p53 antigen capture ELISA also revealed a high titer humoral 
immune  response  (titer  "~1:25,000)  (Fig.  4  B).  Weaker 
binding to PAb 122 alone was again detected, and was com- 
parable with the binding to an irrdevant IgG2b isotype con- 
trol  (anti-Ku mAb N3H10).  Consistent  with  the ELISA 
results, the titers of antibodies to p53 and SVT as determined 
by Western blot ranged from 1:25,000 to 1:100,000 (data not 
shown). 
Time Course of Antibody Production.  A  striking increase 
in IgG1 anti-p53 autoantibodies in the sera of the mice im- 
munized with p53/SVT complex was observed from day 14 
to 42 (Fig.  5 A). In contrast, IgG1 autoantibodies to p53 
were undetectable by ELISA in the sera of mice immunized 
with p53. Sera of the mice immunized with SVT alone were 
either negative (Fig. 5 A) or weakly positive (data not shown) 
for autoantibodies to p53. 
To examine whether the production of autoantibodies to 
p53 could be maintained by endogenous murine p53 once 
initiated by immunization with p53/SVT complexes, serum 
samples  were obtained from the mice for 18 wk after the 
last immunization with p53/SVT complexes. The levels of 
anti-p53 and anti-SVT antibodies in these sera were deter- 
mined by ELISA. As shown in Fig. 5 B, the level of autoanti- 
bodies to p53 feU significantly and in parallel with the level 
of antibodies to SVT. However, the drop in anti-p53 appeared 
more marked than that of anti-SVT. Approximately 60 d after 
the last p53/SVT  injection,  the levels of both  antibodies 
reached a steady state. However, autoantibodies to p53 never 
reached preimmune levels. 
Immunization with affinity-purified p53 alone at day 156 
(127 d  after the last p53/SVT injection) resulted in a dra- 
matic increase in anti-p53 antibodies within 9 d (Fig.  5 B, 
**). The level of anti-p53 on day 165 was comparable with 
that seen on day 42 after three injections of p53/SVT com- 
plexes. In contrast, antibodies to SVT displayed a modest de- 
cline from day 156 to 165, indicating that the anti-p53 re- 
sponse was specific for p53, and not a consequence of  polydonal 
activation. Moreover, the levels of anti-Ig antibodies increased 
only slightly (Fig.  5 B). 
Autoantibody Specificity 
The specificities of the autoantibodies to p53 induced in 
mice immunized with p53/SVT complexes were examined 
further by immunoprecipitating lysates of 3mS-labeled K562 
and SP2/0 cells. The murine anti-p53 sera did not immuno- 
precipitate other proteins from extracts of either cell line, sug- 
gesting that the autoimmune response was specific for p53 
(data not shown). 
Autoimmunity  to  the p53 Tumor Suppressor Protein A 
1.6 
1.2 
1.0  S 
o  ~ 0.8 
~.'  0.6  o 
0.4 
0.2 
￿9  p53/SVT 
￿9  p53 
w  SVT 
0.60 





0.80  /~  ￿9  p53  ￿9  Ig 
I  ~  ~V  SVT **  p53  immunization 
0.20  ~~~V"""~  I 
0.0  ,  ,  ,  0.00  .  , ,  , ,  , ,  , ,  ,  ,  ,  , 
0  14  28  42  40  60  80  100  120  140  160  180 
time (days)  time (days) 
Figure  5.  Analysis of anti-p53  autoantibodies  in mouse sera by ELISA. (/1) Onset of autoantibody  production.  Microtiter plates were coated with 
PAb 122 (anti-p53),  followed by Sf-9 cell lysate containing recombinant  routine p53 or lysis buffer alone, as described in Materials and Methods.  Sera 
were tested at 1:250, followed by allr~line  phosphatase-conjugated  goat anti-mouse IgG1 subclass-specific antibodies at 1:1,250 and p-nitrophenyl phos- 
phate substrate.  Binding to the wells coated with antibody alone was subtracted  from the binding to wells coated with antigen plus antibody.  OD 
(405 nm) is plotted as a function of time (da),s) after the first immunization. (W) Sera from a mouse immunized with p53/SVT complexes; (0) sera 
from a mouse immunized with p53; (V) sera from a mouse immunized with SVT. (B) Immunization of p53/SVT primed mouse with murine p53. 
Levels of IgG1 autoantibodies  to routine p53  (0) and antibodies  to SVT (V) in serial serum samples of a mouse previously injected three times (day 
0,  14, and 28) with p53/SVT complexes were determined by antigen capture  ELISAs as described in Materials and Methods.  On day 156 the mouse 
was immunized with affmity-puritied  murine p53  (* *) and  serum  obtained  9 d hter was tested for anti-p53  and anti-SVT antibodies.  Binding to 
Ig (PAb 101 and PAb 122, respectively) coated wells was subtracted  in each assay. The binding to PAb 101 coated wells in the absence of antigen 
is also shown (W). 
Discussion 
Autoantibodies are detected at increased frequency during 
certain viral infections (26-30) and in some vitally induced 
neoplastic diseases (31). These autoantibodies may sometimes 
be a consequence of nonspecific polyclonal B cell activation, 
whereas in other cases, more specific mechanisms appear to 
be involved.  For example,  rodents carrying SV40-induced 
tumors develop autoantibodies specific for the p53 tumor sup- 
pressor protein, and it has been proposed that the binding 
of p53 to SVT in these tumors may render p53 immuno- 
genic, as if it were a hapten with SVT as the antigenic carrier 
protein (32, 33). However, autoantibodies to p53 have also 
been reported in human breast cancer and murine sarcomas 
that are not induced by SV 40 (34, 35). Since somatic muta- 
tions in p53 represent one step in the pathogenesis of many 
neoplasms (36), the possibility that a T cell response directed 
at somatically mutated p53 might induce autoantibodies to 
p53 in mice carrying SV40 induced tumors could not be ex- 
cluded. Indeed, there is recent evidence that the development 
of autoantibodies to p53 in human neoplastic disease is de- 
pendent on missense mutations (37, 38). The present studies 
suggest that the binding of SVT to wild-type (i.e. unmu- 
tated) p53 may induce autoimmunity by activating T  cells 
spedfic for cryptic epitopes of p53. 
Neoplastic Disease and p53 Mutations Are Not Required to 
Induce Autoantibodies.  The development of autoimmunity 
to p53 does not require SV40-transformed tumor cells or so- 
matic mutation of p53, since a strong, specific autoantibody 
response to p53 was induced by immunizing mice with bio- 
chemically purified p53/SVT complexes. Repeated immuni- 
zation with murine p53 alone did not induce autoantibodies 
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to p53, consistent with immune tolerance to this self antigen. 
Moreover,  since the present studies employed recombinant 
wild-type murine p53/SVT complexes instead of tumor cells, 
which might undergo somatic mutation, it is likely that neo- 
antigenic determinants resulting from mutation of p53 did 
not trigger autoimmunity  in this model. Thus, our data sug- 
gest that the association of certain self proteins with foreign 
antigens may induce autoantibodies specific for the cellular 
components. 
Autoimraunity Is Unlikely to Be Due to Coimmunization with 
Self and Foreign p53.  It has been shown recently that au- 
toantibodies to cytochrome  c can be induced by coimmunizing 
mice with self and foreign cytochrome c, suggesting that au- 
toreactive  B cells activated during an immune response to 
foreign cytochrome c can present self antigen to autoreactive 
T cdls (39, 40). Several lines of evidence argue that the au- 
toantibodies to p53 were not generated by a similar mecha- 
nism. An insect homolog of p53 has not been reported, and 
even if insect p53 exists, there was no evidence that it bound 
to SVT (Fig.  1), in agreement with previous observations 
(17). In addition, a hypothetical insect p53 homolog was not 
immunoprecipitated  by PAb 122, even though p53/SVT com- 
plexes affinity purified using PAb 122, like those purified using 
PAb 101, induced autoantibodies to p53. Moreover, mice im- 
munized with p53 expressed in Sf-9 cells did not develop au- 
toanfibodies, suggesting that the complex of routine p53 with 
SVT was required for inducing autoantibodies. The previous 
observations  that mice carrying SV40-induced tumor cells 
develop autoantibodies to p53 (32, 33) provide additional in- 
direct evidence that the autoantibodies to p53 were not a con- sequence  of immunizing with  a  mixture of foreign and 
self p53. 
Autoantibodies top53 Are Not Cross-reactive  with SVT  Al- 
though not completely excluded, the autoantibodies to p53 
are also unlikdy to have been a cross-reactive population of 
antibodies directed primarily at SVT. Affinity-purified au- 
toantibodies to p53 from the sera of mice immunized with 
p53/SVT complexes were highly specific for p53, whereas 
atranity-purified  antibodies to SVT disphyed no cross-reactivity 
with p53 (Fig. 3 B).  Thus, at least the antibodies reactive 
with p53 and SVT on immunoblots were distinct popula- 
r-ions. Moreover, immunization of p53/SVT primed mice with 
p53 alone boosted the anti-p53, but not the anti-SVT,  re- 
sponse (Fig. 5 B), providing additional evidence that the an- 
tibodies reactive with p53 and SVT were distinct. 
Despite the fact that the affinity-purified antibodies to p53 
and SVT represented distinct populations, some mice im- 
munized with SVT alone produced low levels of autoanti- 
bodies to p53. Most likely, this was related to the formation 
of p53/SVT complexes in vivo after immunizing the mice. 
The p53 antigen bound readily to SVT in vitro, suggesting 
that cdlular p53 released by necrotic cells could bind to the 
affinity beads carrying SVT. Moreover,  injection of 250 ng 
or less of the p53/SVT complexes induced autoantibodies 
to p53, suggesting that even small amounts of the complex 
can trigger autoimmunity (Dong, X., unpublished data). 
p53/SVT Complexes May Induce Autoreactive T Cells Specific 
forp53.  Although immunization with p53/SVT complexes 
was necessary to break tolerance to p53, a subsequent injec- 
tion of p53 alone dicited a brisk secondary autoantibody re- 
sponse (Fig. 5 B). This might be explained in several ways. 
The possibility that autoantibodies to p53 were induced in 
response to the mAb used for affinity purifying p53/SVT 
complexes is unlikely, in view of the low level of antibodies 
specific for PAb 101 and the strong secondary response to 
immunization with affinity-purified  p53 on PAb 122 beads 
(Fig. 5 B). However, a potential role for autoantigen-mimic- 
king idiotypes (41) in the pathogenesis of autoantibodies to 
p53 in this model cannot be excluded completely. 
Another possihle explanation for our data is the initiation 
of autoantibody production by a mechanism involving inter- 
molecular-intrastructural help (11), and its subsequent main- 
tenance by activated p53-specific B cells. Although the produc- 
tion of autoantibodies in response to a complex of self and 
nonself  might be expected to depend on continued availability 
of that complex (3), a role for intermolecular-intrastructural 
help in initiating autoimmunity is not excluded by our data 
if a two-step mechanism is invoked. In the first stage, T cells 
specific for SVT may activate B cells specific for murine p53 
as envisioned by the intermolecular-intras~ hdp model, 
leading to the expression of costimulatory molecules on their 
surface. In a second stage, these activated autoreactive B cells 
might present murine p53 peptides to autoreactive  T  cells 
in a manner analogous to that proposed in the cytochrome 
c model (39, 40), thus accounting for the immune response 
to routine p53 alone after priming with p53/SVT complexes. 
However,  the simplest explanation for our data is a model 
involving altered  antigen processing of self p53. 
The expressed repertoire ofT calls responsive to an exoge- 
nous antigen is focused onto a limited number of major T 
cell-inducing determinants rather than being broadly directed 
against all portions of the antigen (42, 43). This is controlled, 
in part, by MHC-linked genes through a determinant selec- 
tion mechanism in which immunodominant peptides bind 
to MHC molecules that can present the peptide (42, 44). 
Another factor influencing T cell repertoire expression is the 
existence of hindering structures on naturally processed frag- 
ments that differentially affect presentation by different MHC 
molecules (42, 45). These may include structural constraints 
imposed by the tertiary structure of a protein (46) as well 
as intermolecular contacts between subunits of an oligomeric 
antigen (15, 16). 
It has been suggested that T cells responsive to minor an- 
tigenic determinants can evade tolerance because of the rela- 
tively low amounts of peptides suitable for MHC binding 
after in vivo processing of the intact antigen (12). Autoreac- 
tive T cells can be activated under special circumstances, such 
as immunization with artificially processed peptides (13). Al- 
tered antigen processing induced by changing the quaternary 
structure of a complex may represent a second mechanism 
for activating autoreactive T cells. Thus, the binding of SVT 
to p53 might alter processing of p53, resulting in the presen- 
tation of "cryptic" T cell epitopes of self to which tolerance 
is incomplete or nonexistent (12-14,  47). 
A similar mechanism may underlie autoimmunity to p53 
in patients with breast or lung cancer, in whom autoanti- 
bodies are correlated with missense mutations in exons 5 and 
6 (which, perhaps not coincidentally, are located within the 
SVT binding domain of p53) and with binding of the mu- 
tant protein to hsp70 (37, 38, 48). We speculate that altered 
antigen processing,  as a consequence of either the missense 
mutations themselves or binding of hsp70 to the mutant pro- 
tein, may trigger autoimmunity to p53. However, a role of 
T cells specific for the mutant p53 protein cannot be ruled 
out at present. 
Antigen processing might also be altered by autoantibodies 
to p53 in a manner analogous to that proposed above for 
SVT. In this scenario, autoantibodies induced by a mecha- 
nism involving intermolecular-intrastructural help might 
themselves facilitate the presentation of cryptic T  cell epi- 
topes to p53-responsive autoreactive T cells. There is evidence 
for altered processing of antigens bound to different Igs (49), 
and indirect evidence that the binding of autoantibodies to 
antigens can induce new autoantibodies (50-52). Thus, the 
intermolecular-intrastructural help and altered antigen-pro- 
cessing models may not be mutually exr2usive, and both mech- 
anisms could play a role in perpetuating autoimmunity. 
Relevance to Virall  7 Induced Autoimrnunity.  The induction 
of ANAs by immunization with p53/SVT complexes may 
have relevance for the induction of specific autoantibodies in 
viral infections (4) or collagen vascular disease. For example, 
the papovaviruses JC and BK are dosdy related to SV40, pro- 
duce large T  antigens analogous to SVT, and are common 
human pathogens (53).  It would not be surprising to find 
autoantibodies to p53 in sera of patients infected acutely with 
these viruses, or possibly during reactivation of latent infec- 
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pathy (54). ANAs specific for histones and DNA, both of 
which may be physically associated with the p53 protein in 
chromatin, have been described previously in papovavirus in- 
fection, although specificity for p53 was not investigated (55). 
It  is  also  of interest  that  progressive  multifocal  leukoen- 
cephalopathy may complicate SLE, presenting a clinical  pic- 
ture similar to that seen in central nervous system lupus (56). 
It remains to be established,  however, whether either disorder 
is associated with autoantibodies to p53. In view of the wide 
variety of viral antigens known to form comple~es with specific 
cellular proteins, and previous data suggesting that reovirus- 
induced autoantibody production is specific for viraUy infected 
cell types or tissues (28), it is tempting to speculate that other 
complexes of self and nonself might  trigger  autoantibody 
production in certain patients with acute or chronic viral in- 
fections or systemic autoimmune  diseases. 
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